{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:15:31Z","timestamp":1783199731303,"version":"3.54.6"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82525051"],"award-info":[{"award-number":["82525051"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072785"],"award-info":[{"award-number":["82072785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103376"],"award-info":[{"award-number":["82103376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["824B2094"],"award-info":[{"award-number":["824B2094"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.canlet.2026.218606","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:12:07Z","timestamp":1779376327000},"page":"218606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Metabolic checkpoint CPS1 sustains TCA anaplerosis via urea cycle in IDH-mutant gliomas"],"prefix":"10.1016","volume":"654","author":[{"given":"Hao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyuan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-5078","authenticated-orcid":false,"given":"Wei","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218606_bib1","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Cancer Genome Atlas Research","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218606_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2026.218606_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s44178-022-00020-x","article-title":"CACA guidelines for holistic integrative management of glioma","volume":"1","author":"Fan","year":"2022","journal-title":"Holist Integ Oncol"},{"key":"10.1016\/j.canlet.2026.218606_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/neuonc\/noaa168","article-title":"CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p\/19q codeleted oligodendroglioma. Analysis from the initial study design","volume":"23","author":"Jaeckle","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218606_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial","volume":"141","author":"de Botton","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218606_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218606_bib7","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1093\/nop\/npae104","article-title":"Who will benefit from vorasidenib? Review of data from the literature and open questions","volume":"12","author":"Darlix","year":"2025","journal-title":"Neuro-Oncol. Pract."},{"key":"10.1016\/j.canlet.2026.218606_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cell.2017.11.031","article-title":"R-2HG exhibits anti-tumor activity by targeting FTO\/m(6)A\/MYC\/CEBPA signaling","volume":"172","author":"Su","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218606_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218606_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/neuonc\/noaa034","article-title":"Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness","volume":"22","author":"Tiwari","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218606_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cell.2018.08.038","article-title":"Transaminase inhibition by 2-Hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in Glioma","volume":"175","author":"McBrayer","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218606_bib12","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.celrep.2018.02.084","article-title":"Oncogenic IDH1 mutations promote enhanced proline synthesis through PYCR1 to support the maintenance of mitochondrial redox homeostasis","volume":"22","author":"Hollinshead","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218606_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/2159-8290.CD-21-0218","article-title":"Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability","volume":"13","author":"Thomas","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218606_bib14","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/neuonc\/not243","article-title":"Lactate dehydrogenase A silencing in IDH mutant gliomas","volume":"16","author":"Chesnelong","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218606_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-Deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218606_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218606_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s42003-018-0178-4","article-title":"Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction","volume":"1","author":"Cheng","year":"2018","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2026.218606_bib18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218606_bib19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.stem.2025.01.002","article-title":"Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy","volume":"32","author":"Peng","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2026.218606_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chembiol.2020.01.009","article-title":"Small molecule inhibition of CPS1 activity through an allosteric pocket","volume":"27","author":"Yao","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218606_bib21","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.18632\/oncotarget.3330","article-title":"D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth","volume":"6","author":"Ma","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218606_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting glutamine metabolism as a therapeutic strategy for cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218606_bib23","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","article-title":"Vorasidenib: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2026.218606_bib24","first-page":"15","article-title":"Preclinical models of low-grade gliomas","author":"Dasgupta","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218606_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030712","article-title":"Contemporary mouse models in Glioma research","volume":"10","author":"Hicks","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218606_bib26","article-title":"Patient-derived xenograft models: current status, challenges, and innovations in cancer research","volume":"12","author":"Liu","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.canlet.2026.218606_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:27:51Z","timestamp":1783196871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526003691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S0304383526003691"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218606","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic checkpoint CPS1 sustains TCA anaplerosis via urea cycle in IDH-mutant gliomas","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218606"}}